Eli Lilly study suggests Cymbalta reduces core anxiety disorder symptoms

By Elaine Rigoli

Tampa, Fla., March 24 - A new study of about 500 patients evaluating the safety and efficacy of Cymbalta (duloxetine HCl) showed that Cymbalta significantly reduced core anxiety symptoms and associated painful physical symptoms and improved functional impairment associated with the illness, according to a company news release.

In this nine-week study, Cymbalta significantly improved core anxiety symptoms such as anxious mood, fear and tension by 51% in patients taking 60 mg/day and by 50% in patients taking 120 mg/day, compared to an improvement of 32% in patients taking a placebo.

Patients taking both 60 mg/day and 120 mg/day had significantly greater response and remission rates compared to patients taking a placebo, the release said.

In addition, Cymbalta significantly reduced overall pain by 41% and 37%, respectively, compared to 16% in patients taking a placebo.

Indianapolis-based Eli Lilly develops pharmaceutical products by applying research from its own worldwide laboratories and from collaborations with scientific organizations.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.